ALC vs RPRX
Alcon Inc vs Royalty Pharma plc — AI-powered side-by-side comparison
VS
RPRX
Royalty Pharma plc
56
Watch
| Metric | ALC | RPRX |
|---|
| AI Score |
68
|
56
|
| Price |
$75.39
|
$57.79
|
| P/E Ratio |
45.39×
|
23.98×
|
| ROE |
4.4%
|
11.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
54.9%
|
89.4%
|
| Debt / Equity |
0.24×
|
1.31×
|
| Dividend Yield |
0.5%
|
1.6%
|
| RSI (14) |
73.4
|
49.6
|
| Beta |
0.703
|
0.425
|
| Expected Upside |
+11.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALC versus RPRX.
ALC leads by 12 points.
ALC scores 68/100 (Buy) versus RPRX at 56/100 (Watch).
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
RPRX Committee View
60% agreement
5 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — p/e of 40.9 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 40.9 is expensive by classic value standards — Value
- EPS declining -15.9% YoY despite any revenue growth — Growth
- MACD histogram negative -- bearish momentum — Technical